Indirect medical costs in the first 3 years of rheumatoid arthritis: Comparison of current methodological approaches

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 4, 2002, Pages 313-318

  Merkesdal, Sonja ^a   Ruof, Jörg ^a   Mittendorf, Thomas ^a   Zeidler, Henning ^a   Mau, Wilfried ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cost of illness; Friction costs; Human capital approach; Indirect costs; Productivity loss; Standardization scheme

Indexed keywords

ABSENTEEISM; ADULT; CAPITAL; CHRONIC DISEASE; CONTROLLED STUDY; COST CONTROL; COST OF ILLNESS; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; POPULATION RESEARCH; PROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; STANDARDIZATION; WORK DISABILITY;

EID: 0036053999     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.4.313     Document Type: Review

References (32)

1. The cost of rheumatoid arthritis
2. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: A 12 year study
3. The cost of rheumatoid arthritis: Absolute, incremental, and marginal estimates
4. The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs
5. Modeling the lifetime costs of rhematoid arthritis
6. An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline
7. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists
8. Economic consequences of the progression of rheumatoid arthritis in Sweden
9. Musculoskeletal conditions and employment
10. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis
11. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
12. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis (RA) in the UK
13. Cost-effectiveness of Infliximab (Remicade) in Sweden
14. Health economic research in rheumatoid arthritis
15. OMERACT: Economic evaluations and health policy
16. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls
17. Treatment of rheumatoid arthritis - Does it affect society's cost for the disease?
18. Indirect medical costs in early rheumatoid arthritis: Composition of and changes in indirect costs within the first three years of disease
19. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis
20. Cost assessment instrument in rheumatology: Evaluation of applied instrument characteristics
21. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
22. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - Revidierte Fassung des Hannoveraner Konsens
23. Complementary analyses in economic evaluation of health care
24. Health Economic Evaluation
25. Reducing work disability associated with rheumatoid arthritis: Identification of additional risk factors and persons likely to benefit from intervention
26. Early rheumatoid arthritis - Some social, economical, and psychological aspects
27. Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: Results of a tree structured analysis using recpam
28. Cost-Effectiveness in health and medicine
29. Impact of etanercept (ENBREL) on health care use and employment in early RA
30. Report of the OMERACT Task Force on Economic Evaluation